Emmaus Life Sciences adds Henry Du to board
Emmaus Life Sciences, Inc. appointed Henry H. Du to its Board of Directors by written consent on April 16, 2026, filling the vacancy created by the recent resignation of Jon Kuwahara.
Rhea-AI Filing Summary
Emmaus Life Sciences, Inc. appointed Henry H. Du to its Board of Directors by written consent on April 16, 2026, filling the vacancy created by the recent resignation of Jon Kuwahara. He is also expected to replace Mr. Kuwahara as the sole member of the Board’s Audit Committee.
Mr. Du, age 48, is Vice President – Finance Accounting and interim Chief Financial Officer of Alpha Cognition, Inc., a biopharmaceutical company, and is a Certified Public Accountant with a Bachelor of Arts degree from Claremont McKenna College. Emmaus states there are no family relationships or related-party transactions requiring disclosure, and that he will be compensated like its other directors.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Appointment date: April 16, 2026
Director age: 48 years
Alpha Cognition role start: October 2024
3 metrics
Appointment date
April 16, 2026
Date directors appointed Henry H. Du to the Board
Director age
48 years
Age of Henry H. Du as disclosed
Alpha Cognition role start
October 2024
Start date of Du’s role at Alpha Cognition, Inc.
Key Terms
Audit Committee, emerging growth company, Regulation S-K
3 terms
Audit Committee financial
"expected to also be appointed to replace Mr. Kuwahara as the sole member of the Audit Committee of the Board"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
emerging growth company regulatory
"Securities registered pursuant to Section 12(b of the Act ... Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Regulation S-K regulatory
"not party to any current or proposed transaction for which disclosure is required under Item 404(a) of Regulation S-K"
A set of U.S. Securities and Exchange Commission rules that tell public companies which narrative and qualitative details must be disclosed in filings, such as risk factors, management discussion, executive pay, legal proceedings and business description. Think of it as a standardized checklist or blueprint that ensures investors get the same types of background information from every company so they can compare risks, management quality and strategy before making investment decisions.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did Emmaus Life Sciences (EMMA) disclose?
Emmaus Life Sciences disclosed that its directors appointed Henry H. Du to the Board to fill a vacancy created by the recent resignation of Jon Kuwahara. Du is also expected to serve as the sole member of the company’s Audit Committee, replacing Kuwahara in that role.
What is Henry H. Du’s current role outside Emmaus Life Sciences (EMMA)?
Henry H. Du currently serves as Vice President – Finance Accounting and interim Chief Financial Officer of Alpha Cognition, Inc., a biopharmaceutical company in Grapevine, Texas. Alpha Cognition focuses on developing novel therapeutics for debilitating neurodegenerative disorders, a background relevant to Emmaus’s life sciences focus.
Will Henry H. Du’s compensation at Emmaus Life Sciences (EMMA) differ from other directors?
Emmaus Life Sciences states that Henry H. Du is expected to be compensated for his services in the same manner as its other directors. The company does not describe any special compensation arrangements or unique benefits, indicating he will participate under the standard director compensation framework.
What are Henry H. Du’s professional qualifications for the Emmaus Life Sciences (EMMA) board?
Henry H. Du is a Certified Public Accountant and has held senior finance and accounting roles at various life sciences and other companies. He holds a Bachelor of Arts degree from Claremont McKenna College, providing both technical accounting expertise and industry experience to Emmaus’s Board of Directors.
AI-generated analysis. How Rhea-AI works. Not financial advice.
